相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Seo Yun Kim et al.
TUBERCULOSIS AND RESPIRATORY DISEASES (2019)
Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation
Tomohiro Tanaka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors
Ludovic Menard et al.
CANCER RESEARCH (2018)
Cetuximab for treating non-small cell lung cancer
Luca Mazzarella et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin
Yong Hu et al.
ONCOTARGETS AND THERAPY (2017)
EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
Xueli Nan et al.
ONCOTARGET (2017)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2
D. Zhao et al.
ONCOGENE (2015)
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
S. E. D. C. Jorge et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
Ukhyun Jo et al.
ONCOTARGET (2014)
Monoclonal antibodies in lung cancer
Yujiong Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Predicting Survival in Patients with Advanced Non-squamous Non-small Cell Lung Cancer: Validating the Extent of Metastasis
Dong Soo Lee et al.
CANCER RESEARCH AND TREATMENT (2013)
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
Jenn-Yu Wu et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2010)
Epidermal Growth Factor Receptor Translocation to the Mitochondria REGULATION AND EFFECT
Michelle L. Demory et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Endocytosis and signalling: intertwining molecular networks
Alexander Sorkin et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2009)
Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
Jeet Gandhi et al.
PLOS ONE (2009)
Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation
Sara Sigismund et al.
DEVELOPMENTAL CELL (2008)
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
Kirstine Roepstorff et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2008)
MYC - TIMELINE Reflecting on 25 years with MYC
Natalie Meyer et al.
NATURE REVIEWS CANCER (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Proteasome-independent functions of ubiquitin in endocytosis and signaling
Debdyuti Mukhopadhyay et al.
SCIENCE (2007)
Powering membrane traffic in endocytosis and recycling
Thierry Soldati et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Integration of EGFR inhibitors with radiochemotherapy
Mukesh K. Nyati et al.
NATURE REVIEWS CANCER (2006)
Endocytic adaptors:: recruiters, coordinators and regulators
Lymarie Maldonado-Baez et al.
TRENDS IN CELL BIOLOGY (2006)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
F Cappuzzo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
The ErbB receptors and their ligands in cancer: An overview
N Normanno et al.
CURRENT DRUG TARGETS (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling
C Le Roy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Timeline - Gefitinib - a novel targeted approach to treating cancer
RS Herbst et al.
NATURE REVIEWS CANCER (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Endocytosis and vesicle trafficking
PR Evans et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2002)
Nuclear localization of EGF receptor and its potential new role as a transcription factor
SY Lin et al.
NATURE CELL BIOLOGY (2001)
分享论文
